Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC increased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 28.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 189,347 shares of the company's stock after buying an additional 42,302 shares during the period. Janus Henderson Group PLC owned about 0.39% of Amphastar Pharmaceuticals worth $7,030,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in AMPH. Smartleaf Asset Management LLC boosted its stake in Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after purchasing an additional 493 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after purchasing an additional 871 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after purchasing an additional 348 shares during the last quarter. Huntington National Bank boosted its stake in Amphastar Pharmaceuticals by 36.9% during the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock worth $50,000 after purchasing an additional 361 shares during the last quarter. Finally, TD Private Client Wealth LLC boosted its stake in Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock worth $78,000 after purchasing an additional 388 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Wells Fargo & Company lowered their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Piper Sandler cut their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $32.33.

Insider Buying and Selling

In other news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 5,231 shares of company stock valued at $142,752. 27.50% of the stock is currently owned by insiders.

Amphastar Pharmaceuticals Trading Up 1.1%

Shares of AMPH traded up $0.27 during midday trading on Friday, reaching $24.47. The company had a trading volume of 548,566 shares, compared to its average volume of 480,046. Amphastar Pharmaceuticals, Inc. has a 1-year low of $22.64 and a 1-year high of $53.96. The stock has a market cap of $1.16 billion, a PE ratio of 8.16, a price-to-earnings-growth ratio of 2.19 and a beta of 0.78. The firm has a 50 day simple moving average of $25.20 and a 200-day simple moving average of $33.05. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.